PUBLISHER: Grand View Research | PRODUCT CODE: 1529868
PUBLISHER: Grand View Research | PRODUCT CODE: 1529868
U.S. And Europe On-body Injectors Market Size, Share & Trends Analysis Report By Technology (Spring-based, Motor-driven, Rotary Pump), By Application (Diabetes, Cardiovascular Disease), By End Use, By Region, And Segment Forecasts, 2024 - 2030
U.S. And Europe On-body Injectors Market Growth & Trends:
The U.S. and Europe on-body injectors market size is anticipated to reach USD 5.45 billion by 2030 and is projected to grow at a CAGR 11.27% from 2024 to 2030, according to a new report by Grand View Research, Inc., due to several key factors. Primarily, the rising incidence of chronic illnesses such as diabetes and cancer has amplified the demand for advanced drug delivery systems.
According to June 2024 data from the American Heart Association, over 184 million people, or more than 61% of the U.S. population, are projected to have some form of cardiovascular disease (CVD). Total CVD-related costs are expected to triple to USD 1.8 trillion by 2050. On-body injectors provide a convenient and less intrusive way to administer medications, appealing especially to patients needing regular self-administration, thereby enhancing treatment adherence and overall therapeutic effectiveness. Moreover, the increasing elderly population in these regions underscores the necessity for effective drug delivery solutions, further driving market expansion.
In addition, the regulatory environment in the U.S. and Europe has been supportive of the development and commercialization of on-body injectors. Regulatory bodies such as the FDA and EMA have established clear guidelines and streamlined approval processes for these devices, ensuring their safety and efficacy. This regulatory support has encouraged manufacturers to innovate and bring new products to market more swiftly. Furthermore, the harmonization of regulatory standards across these regions has facilitated easier market entry and expansion for global companies, contributing to the overall growth of the on-body injectors market.
Moreover, market players such as BD, Stevanato Group, and Coherus BioSciences are leading in innovation, introducing advanced on-body delivery systems. Developments include customizable dosing options, enhanced connectivity features, and improved user interfaces to optimize patient convenience and treatment adherence. These advancements cater to the rising demand for efficient drug delivery solutions, particularly in managing conditions such as diabetes and autoimmune diseases. For instance, in October 2022, Nemera and Zollner entered into a partnership to create electronic drug delivery devices, commencing with Nemera's Symbioze, a high-capacity wearable injection device. Under this collaboration, Zollner will manage the electronics and software development for the Symbioze device. Such collaborative efforts are crucial in addressing the complex needs of chronic disease management, thereby driving the growth of the on-body injectors market in the U.S. and Europe.
Furthermore, increasing investment in healthcare infrastructure and the rising adoption of advanced medical devices in both the U.S. and Europe have fostered market growth. Governments and private entities are allocating substantial resources to modernize healthcare facilities and improve patient care standards. This investment includes the adoption of cutting-edge medical technologies, such as on-body injectors, which streamline treatment processes and reduce hospital stays.
U.S. And Europe On-body Injectors Market Report Highlights:
- The spring-based segment held the largest share of 40.89% in 2023, spring-based on-body injectors are effective devices offering numerous benefits to both patients and healthcare providers. One of the primary factors contributing to the market growth includes the increasing prevalence of chronic diseases such as diabetes and autoimmune disorders, which require regular & precise medication delivery
- The diabetes segment held the largest share of 25.45% in 2023. On-body injectors are effective tools in diabetes management because they ensure precise and consistent delivery of medication. The rising healthcare expenditure on diabetes care further supports the adoption of advanced technologies such as on-body injectors
- The hospitals & clinics segment held the largest share of 46.76% in 2023. With the population expanding and aging, there is an increasing demand for healthcare services, especially for chronic ailments such as diabetes, cardiovascular diseases, and autoimmune disorders
- U.S. on-body injectors market dominated the overall market and accounted for the 51.15%-revenue share in 2023, driven by several factors, including increased healthcare spending, government initiatives, and higher disposable incomes. Additionally, favorable reimbursement scenarios, a rise in chronic diseases requiring long-term care, and high per capita income are expected to further stimulate market expansion
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Segment Definitions
- 1.2.1. Technology
- 1.2.2. Application
- 1.2.3. End Use
- 1.2.4. Regional Scope
- 1.2.5. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Technology outlook
- 2.2.2. Application outlook
- 2.2.3. End Use outlook
- 2.3. Regional outlook
- 2.4. Competitive Insights
Chapter 3. U.S. and Europe On-body Injectors Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. U.S. and Europe On-body Injectors Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Bargaining power of suppliers
- 3.3.1.2. Bargaining power of buyers
- 3.3.1.3. Threat of substitutes
- 3.3.1.4. Threat of new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic landscape
- 3.3.2.3. Social landscape
- 3.3.2.4. Technological landscape
- 3.3.2.5. Environmental landscape
- 3.3.2.6. Legal landscape
- 3.3.1. Industry Analysis - Porter's
Chapter 4. U.S. and Europe On-body Injectors Market: Technology Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. U.S. and Europe On-body Injectors Market: Technology Movement Analysis
- 4.3. U.S. and Europe On-body Injectors Market by Technology Outlook (USD Billion)
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.5. Spring-based
- 4.5.1. Spring-based Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 4.6. Motor-driven
- 4.6.1. Motor-driven Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 4.7. Rotary Pump
- 4.7.1. Rotary Pump Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 4.8. Expanding Battery
- 4.8.1. Expanding battery Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 4.9. Others
- 4.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 5. U.S. and Europe On-body Injectors Market: Application Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. U.S. and Europe On-body Injectors Market: Application Movement Analysis
- 5.3. U.S. and Europe On-body Injectors Market by Application Outlook (USD Billion)
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.5. Oncology
- 5.5.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 5.6. Diabetes
- 5.6.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 5.7. Cardiovascular Disease
- 5.7.1. Cardiovascular disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 5.8. Autoimmune Disease
- 5.8.1. Autoimmune disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 5.9. Others
- 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 6. U.S. and Europe On-body Injectors Market: End Use Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. U.S. and Europe On-body Injectors Market: End Use Movement Analysis
- 6.3. U.S. and Europe On-body Injectors Market by End Use Outlook (USD Billion)
- 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.5. Hospitals & Clinics
- 6.5.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.6. Home Care Settings
- 6.6.1. Home Care Settings Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.7. Others
- 6.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 7. U.S. and Europe On-body Injectors Market: Regional Estimates & Trend Analysis
- 7.1. Regional Dashboard
- 7.2. Regional U.S. and Europe On-body Injectors Market movement analysis
- 7.3. U.S. and Europe On-body Injectors Market: Regional Estimates & Trend Analysis by Technology, Application & End-use
- 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 7.5. U.S.
- 7.5.1. U.S. On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.6. Europe
- 7.6.1. Europe U.S. and Europe On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 8. Competitive Landscape
- 8.1. Market Participant Categorization
- 8.2. Key Company Profiles
- 8.2.1. West Pharmaceutical Services, Inc.
- 8.2.1.1. Company overview
- 8.2.1.2. Financial performance
- 8.2.1.3. Product benchmarking
- 8.2.1.4. Strategic initiatives
- 8.2.2. Stevanato Group
- 8.2.2.1. Company overview
- 8.2.2.2. Financial performance
- 8.2.2.3. Product benchmarking
- 8.2.2.4. Strategic initiatives
- 8.2.3. BD
- 8.2.3.1. Company overview
- 8.2.3.2. Financial performance
- 8.2.3.3. Product benchmarking
- 8.2.3.4. Strategic initiatives
- 8.2.4. Stevanato Group
- 8.2.4.1. Company overview
- 8.2.4.2. Financial performance
- 8.2.4.3. Product benchmarking
- 8.2.4.4. Strategic initiatives
- 8.2.5. Enable Injections
- 8.2.5.1. Company overview
- 8.2.5.2. Financial performance
- 8.2.5.3. Product benchmarking
- 8.2.5.4. Strategic initiatives
- 8.2.6. Nemera
- 8.2.6.1. Company overview
- 8.2.6.2. Financial performance
- 8.2.6.3. Product benchmarking
- 8.2.6.4. Strategic initiatives
- 8.2.7. Debiotech SA
- 8.2.7.1. Company overview
- 8.2.7.2. Financial performance
- 8.2.7.3. Product benchmarking
- 8.2.7.4. Strategic initiatives
- 8.2.8. AbbVie, Inc.
- 8.2.8.1. Company overview
- 8.2.8.2. Financial performance
- 8.2.8.3. Product benchmarking
- 8.2.8.4. Strategic initiatives
- 8.2.9. Coherus BioSciences, Inc
- 8.2.9.1. Company overview
- 8.2.9.2. Financial performance
- 8.2.9.3. Product benchmarking
- 8.2.9.4. Strategic initiatives
- 8.2.10. Gerresheimer AG
- 8.2.10.1. Company overview
- 8.2.10.2. Financial performance
- 8.2.10.3. Product benchmarking
- 8.2.10.4. Strategic initiatives
- 8.2.11. E3D Elcam Drug Delivery Devices
- 8.2.11.1. Company overview
- 8.2.11.2. Financial performance
- 8.2.11.3. Product benchmarking
- 8.2.11.4. Strategic initiatives
- 8.2.1. West Pharmaceutical Services, Inc.
List of Tables
- Table 1 List of Secondary Sources
- Table 2 List of Abbreviations
- Table 3 U.S. and Europe on-body injectors market, by technology, 2018 - 2030 (USD Billion)
- Table 4 U.S. and Europe on-body injectors market, by application, 2018 - 2030 (USD Billion)
- Table 5 U.S. and Europe on-body injectors market, by end use, 2018 - 2030 (USD Billion)
- Table 6 U.S. on-body injectors market, by technology, 2018 - 2030 (USD Billion)
- Table 7 U.S. on-body injectors market, by application, 2018 - 2030 (USD Billion)
- Table 8 U.S. on-body injectors market, by end use, 2018 - 2030 (USD Billion)
- Table 9 Europe on-body injectors market, by country, 2018 - 2030 (USD Billion)
- Table 10 Europe on-body injectors market, by technology, 2018 - 2030 (USD Billion)
- Table 11 Europe on-body injectors market, by application, 2018 - 2030 (USD Billion)
- Table 12 Europe on-body injectors market, by end use, 2018 - 2030 (USD Billion)
List of Figures
- Fig. 1 Information procurement
- Fig. 2 Primary research pattern
- Fig. 3 Market research approaches
- Fig. 4 Value chain-based sizing & forecasting
- Fig. 5 Market formulation & validation
- Fig. 6 U.S. and Europe on-body injectors market segmentation
- Fig. 7 Market driver analysis (current & future impact)
- Fig. 8 Market restraint analysis (current & future impact)
- Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
- Fig. 10 Porter's five forces analysis
- Fig. 11 U.S. and Europe on-body injectors market, technology outlook key takeaways (USD Billion)
- Fig. 12 U.S. and Europe on-body injectors market: technology movement analysis 2023 & 2030 (USD Billion)
- Fig. 13 Spring-based market revenue estimates and forecasts, 2018 - 2030 (USD Billion)
- Fig. 14 Motor-driven market revenue estimates and forecasts, 2018 - 2030 (USD Billion)
- Fig. 15 Rotary pump market revenue estimates and forecasts, 2018 - 2030 (USD Billion)
- Fig. 16 Expanding battery market revenue estimates and forecasts, 2018 - 2030 (USD Billion)
- Fig. 17 Others market revenue estimates and forecasts, 2018 - 2030 (USD Billion)
- Fig. 18 U.S. and Europe on-body injectors market, application outlook key takeaways (USD Billion)
- Fig. 19 U.S. and Europe on-body injectors market: Application movement analysis 2023 & 2030 (USD Billion)
- Fig. 20 Oncology market revenue estimates and forecasts, 2018 - 2030 (USD Billion)
- Fig. 21 Diabetes market revenue estimates and forecasts, 2018 - 2030 (USD Billion)
- Fig. 22 Cardiovascular disease market revenue estimates and forecasts, 2018 - 2030 (USD Billion)
- Fig. 23 Autoimmune disease market revenue estimates and forecasts, 2018 - 2030 (USD Billion)
- Fig. 24 Others market revenue estimates and forecasts, 2018 - 2030 (USD Billion)
- Fig. 25 U.S. and Europe on-body injectors market, end use outlook key takeaways (USD Billion)
- Fig. 26 U.S. and Europe on-body injectors market: end use movement analysis 2023 & 2030 (USD Billion)
- Fig. 27 Hospitals & clinics market revenue estimates and forecasts, 2018 - 2030 (USD Billion)
- Fig. 28 Home care settings market revenue estimates and forecasts, 2018 - 2030 (USD Billion)
- Fig. 29 Others market revenue estimates and forecasts, 2018 - 2030 (USD Billion)
- Fig. 30 U.S. and Europe on-body injectors market: regional key takeaways (USD Billion)
- Fig. 31 U.S. and Europe on-body injectors market: regional outlook, 2023 & 2030 (USD Billion)
- Fig. 32 U.S. on-body injectors market estimates and forecasts, 2018 - 2030 (USD Billion)
- Fig. 33 Europe on-body injectors market estimates and forecasts, 2018 - 2030 (USD Billion)
- Fig. 34 List of key emerging company's/technology disruptors/innovators
